IP Library Granted Patent US 11,944,658
Granted Patent B2
US 11,944,658 · App. 17/238,743 · Granted Apr 2, 2024

Methods of heat inactivation of adenovirus

Inventors: Christopher J. Morrison (Arlington, MA); James D. Maratt (Belmont, MA)
Assignee: Ultragenyx Pharmaceutical Inc.
A61K35/761C12N7/00C12N15/85C12N15/86C12N2523/00C12N2710/10361C12N2750/14143C12N2750/14151
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,944,658
App. No.
17/238,743
Granted
Apr 2, 2024
Kind
B2
Abstract

The present disclosure generally relates to methods of protecting the genomic integrity and/or biological activity of AAV viral particles in a sample containing both AAV particles and helper virus particles during heat inactivation. The methods include heating, to a temperature greater than or equal to 45′C, a sample containing helper virus particles, AAV particles, and a buffer. The buffer includes a concentration of 10 mM or greater kosmotropic salts and/or a concentration of 10 mM or greater of divalent or trivalent cations.

Claims (22)

1. A method of inactivating helper virus in a sample containing helper virus, adeno-associated virus particles, and a buffer comprising a concentration of 25 mM to 500 mM of divalent or trivalent cations, or a concentration of 0.5 M to 0.6 M of kosmotropic salts, wherein the method comprises:

heating the sample to a temperature of 45° C. to 55° C.,

and maintaining the sample at the temperature for a time period of 1 minute to 6 hours, thereby inactivating helper virus.

2. The method of claim 1 , wherein the sample is maintained at the temperature for a time period of 10 to 180 minutes.

3. The method of claim 1 , wherein the method results in a log reduction of helper virus of 6.3 or greater.

4. The method of claim 1 , wherein the adeno-associated virus particle comprises a genome of approximately or more than 4.7 kb of DNA.

5. The method of claim 1 , wherein the buffer further comprises a chaotropic salt.

6. The method of claim 1 , wherein the buffer further comprises a polyol selected from the group consisting of: glycerol, propylene glycol, and 1,6-Hexanediol.

7. The method of claim 1 , wherein the buffer maintains a pH of 3.0 to 10.0 at temperatures of 4° C. to 70° C.

8. The method of claim 1 , wherein the buffer further comprises: 40 mM bis-tris propane, 20 mM HEPES, 20 mM citrate, 200 mM NaCl, and 0.001% (w/v) Pluronic F68.

9. The method of claim 7 , wherein the buffer is a Tris buffer, a phosphate buffer, or a triazolamine buffer.

10. The method of claim 1 , wherein the helper virus is an adenovirus.

11. The method of claim 10 , where the adenovirus is Ad5.

12. The method of claim 1 , wherein the concentration of divalent or trivalent cations is 25 mM to 400 mM.

13. The method of claim 1 , wherein the buffer-comprises divalent or trivalent cations of a metal selected from the group consisting of: Mg, Ca, Mn, Ni, Zn, Co, Sr, Cu, Cr, Fe, and Sc.

14. The method of claim 13 , wherein the cations are selected from the group consisting of: Mg 2+ , Ca 2+ , Mn 2+ , Ni 2+ , Zn 2+ , Co 2+ , Sr 2+ , Cu 2+ and Cr 2+ .

15. The method of claim 14 wherein the cations are Ca 2+ .

16. The method of claim 14 wherein the cations are Mg 2+ .

17. The method of claim 13 , wherein the cations are Sc 3+ .

18. The method of claim 1 , wherein the buffer comprises a kosmotropic salt selected from the group consisting of ammonium sulfate, ammonium acetate, sodium citrate, sodium acetate, sodium sulfate, potassium phosphate, and cesium chloride.

19. The method of claim 18 , wherein the buffer comprises ammonium sulfate.

20. The method of claim 18 , wherein the concentration of kosmotropic salts is 0.5 M.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2022
From: MORRISON, CHRISTOPHER J.; MARATT, JAMES D.
To: DIMENSION THERAPEUTICS, INC.
Reel/Frame 059046/0432 →
MERGER AND CHANGE OF NAME Recorded Feb 18, 2022
From: DIMENSION THERAPEUTICS, INC.; ULTRAGENYX PHARMACEUTICAL INC.
To: ULTRAGENYX PHARMACEUTICAL INC.
Reel/Frame 059046/0858 →
Continuity (3)
Continuation 16085177
Provisional Application 62314116 · Mar 28, 2016
Related Publication 20220072073A1 · Mar 10, 2022